Carolyn Owen - Concepedia

Author

Carolyn Owen

Also Known As

C OWEN, C Owen, C. J. Owen, C. Owen, C.J. Owen, Carolyn J Owen, Carolyn J. Owen, Carolyn Jane Owen, Carolyn Owen, Owen, C

228

Publications

11K

Citations

H-Index

Concepts

All Affiliations

University of Calgary Medical University of Lodz AbbVie (United States)Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Copernicus Memorial Hospital

About

Carolyn Owen is an author at University of Calgary specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.5K
2	Health Sciences	12	13	1.1K
3	Cellular Therapies	3	3	84
4	Public Health	1	1	36
5	Blood Transplantation	1	1	15

Carolyn Owen

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, New England Journal of Medicine	2015	1.5K
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Valentin Goede, Kirsten Fischer, Raymonde Busch, New England Journal of Medicine	2014	1.5K
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, New England Journal of Medicine	2018	927
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, New England Journal of Medicine	2018	881
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Robert Marcus, Andrew Davies, Kiyoshi Ando, New England Journal of Medicine	2017	764
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Jan A. Burger, Paul M. Barr, Tadeusz Robak, Leukemia	2019	447
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study Arnon P. Kater, John F. Seymour, Peter Hillmen, Journal of Clinical Oncology	2018	294
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Paul M. Barr, Carolyn Owen, Tadeusz Robak, Blood Advances Ibrutinib Vs 9Chronic Lymphocytic LeukemiaImmunologyPharmacotherapyFirst-line Ibrutinib Treatment	2022	246
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy Carolyn Owen, Cynthia L. Toze, Anna Koochin, Blood	2008	240
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study Arnon P. Kater, Jenny Wu, Thomas J. Kipps, Journal of Clinical Oncology	2020	209

Page 1